These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18165889)

  • 1. Limited uptake of hepatitis C treatment among injection drug users.
    Mehta SH; Genberg BL; Astemborski J; Kavasery R; Kirk GD; Vlahov D; Strathdee SA; Thomas DL
    J Community Health; 2008 Jun; 33(3):126-33. PubMed ID: 18165889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.
    Falade-Nwulia O; Irvin R; Merkow A; Sulkowski M; Niculescu A; Olsen Y; Stoller K; Thomas DL; Latkin C; Mehta SH
    J Subst Abuse Treat; 2019 May; 100():45-51. PubMed ID: 30898327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
    Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
    Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.
    Strathdee SA; Latka M; Campbell J; O'Driscoll PT; Golub ET; Kapadia F; Pollini RA; Garfein RS; Thomas DL; Hagan H;
    Clin Infect Dis; 2005 Apr; 40 Suppl 5(Suppl 5):S304-12. PubMed ID: 15768339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012.
    Li L; Assanangkornchai S; Duo L; McNeil E; Li J
    PLoS One; 2014; 9(9):e106899. PubMed ID: 25203256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.
    Myles A; Mugford GJ; Zhao J; Krahn M; Wang PP
    Can J Gastroenterol; 2011 Mar; 25(3):135-9. PubMed ID: 21499577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project.
    Caiaffa WT; Mingoti SA; Proietti FA; Carneiro-Proietti AB; Silva RC; Lopes AC; Doneda D
    J Urban Health; 2003 Mar; 80(1):106-14. PubMed ID: 12612100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago.
    Boodram B; Golub ET; Ouellet LJ
    Drug Alcohol Depend; 2010 Sep; 111(1-2):136-45. PubMed ID: 20472373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.
    Souliotis K; Agapidaki E; Papageorgiou M; Voudouri N; Contiades X
    Int J Equity Health; 2017 Jun; 16(1):101. PubMed ID: 28615023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis.
    Xia X; Luo J; Bai J; Yu R
    Public Health; 2008 Oct; 122(10):990-1003. PubMed ID: 18486955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low knowledge and perceived Hepatitis C risk despite high risk behaviour among injection drug users in Kathmandu, Nepal.
    Loewinger G; Sharma B; Karki DK; Khatiwoda P; Kainee S; Poudel KC
    Int J Drug Policy; 2016 Jul; 33():75-82. PubMed ID: 27318773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.
    Nasir A; Todd CS; Stanekzai MR; Bautista CT; Botros BA; Scott PT; Strathdee SA; Tjaden J
    Int J Drug Policy; 2011 Mar; 22(2):145-52. PubMed ID: 21146392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain.
    Santana Rodríguez OE; Malé Gil ML; HernándezSantana JF; Limiñana Cañal JM; Martín Sánchez AM
    Eur J Epidemiol; 1998 Sep; 14(6):555-61. PubMed ID: 9794122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
    AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbidities among HIV-infected injection drug users in Chennai, India.
    Solomon SS; Hawcroft CS; Narasimhan P; Subbaraman R; Srikrishnan AK; Cecelia AJ; Suresh Kumar M; Solomon S; Gallant JE; Celentano DD
    Indian J Med Res; 2008 May; 127(5):447-52. PubMed ID: 18653907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a general practice based hepatitis C virus screening intervention.
    Anderson EM; Mandeville RP; Hutchinson SJ; Cameron SO; Mills PR; Fox R; Ahmed S; Taylor A; Spence E; Goldberg DJ
    Scott Med J; 2009 Aug; 54(3):3-7. PubMed ID: 19728405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in blood-borne infection risk among injection drug users.
    Mehta SH; Astemborski J; Kirk GD; Strathdee SA; Nelson KE; Vlahov D; Thomas DL
    J Infect Dis; 2011 Mar; 203(5):587-94. PubMed ID: 21282191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations.
    Backus LI; Boothroyd D; Deyton LR
    AIDS; 2005 Oct; 19 Suppl 3():S13-9. PubMed ID: 16251809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.